476 related articles for article (PubMed ID: 29022265)
21. Diabetic cardiomyopathy and oxidative stress: role of antioxidants.
Thandavarayan RA; Giridharan VV; Watanabe K; Konishi T
Cardiovasc Hematol Agents Med Chem; 2011 Oct; 9(4):225-30. PubMed ID: 21902660
[TBL] [Abstract][Full Text] [Related]
22. The vulnerable myocardium. Diabetic cardiomyopathy.
Bugger H; Bode C
Hamostaseologie; 2015; 35(1):17-24. PubMed ID: 25408270
[TBL] [Abstract][Full Text] [Related]
23. Pathophysiological mechanisms of diabetic cardiomyopathy and the therapeutic potential of epigallocatechin-3-gallate.
Al Hroob AM; Abukhalil MH; Hussein OE; Mahmoud AM
Biomed Pharmacother; 2019 Jan; 109():2155-2172. PubMed ID: 30551473
[TBL] [Abstract][Full Text] [Related]
24. [Diabetic cardiomyopathy].
Huang YQ; Wang X; Kong W
Sheng Li Ke Xue Jin Zhan; 2010 Feb; 41(1):31-6. PubMed ID: 21417012
[TBL] [Abstract][Full Text] [Related]
25. Exercise as A Potential Therapeutic Target for Diabetic Cardiomyopathy: Insight into the Underlying Mechanisms.
Seo DY; Ko JR; Jang JE; Kim TN; Youm JB; Kwak HB; Bae JH; Kim AH; Ko KS; Rhee BD; Han J
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31842522
[TBL] [Abstract][Full Text] [Related]
26. Oxidative stress and diabetic cardiomyopathy: a brief review.
Cai L; Kang YJ
Cardiovasc Toxicol; 2001; 1(3):181-93. PubMed ID: 12213971
[TBL] [Abstract][Full Text] [Related]
27. Diabetic cardiomyopathy: pathophysiological mechanisms and cardiac dysfuntion.
Goyal BR; Mehta AA
Hum Exp Toxicol; 2013 Jun; 32(6):571-90. PubMed ID: 23174745
[TBL] [Abstract][Full Text] [Related]
28. Combined metoprolol and ascorbic acid treatment prevents intrinsic damage to the heart during diabetic cardiomyopathy.
Saran V; Sharma V; Wambolt R; Yuen VG; Allard M; McNeill JH
Can J Physiol Pharmacol; 2014 Oct; 92(10):827-37. PubMed ID: 25229873
[TBL] [Abstract][Full Text] [Related]
29. Apocynin influence on oxidative stress and cardiac remodeling of spontaneously hypertensive rats with diabetes mellitus.
Rosa CM; Gimenes R; Campos DH; Guirado GN; Gimenes C; Fernandes AA; Cicogna AC; Queiroz RM; Falcão-Pires I; Miranda-Silva D; Rodrigues P; Laurindo FR; Fernandes DC; Correa CR; Okoshi MP; Okoshi K
Cardiovasc Diabetol; 2016 Sep; 15(1):126. PubMed ID: 27585437
[TBL] [Abstract][Full Text] [Related]
30. Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus.
Nakamura K; Miyoshi T; Yoshida M; Akagi S; Saito Y; Ejiri K; Matsuo N; Ichikawa K; Iwasaki K; Naito T; Namba Y; Yoshida M; Sugiyama H; Ito H
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408946
[TBL] [Abstract][Full Text] [Related]
31. Cardiomyopathy in obesity, insulin resistance and diabetes.
Nakamura M; Sadoshima J
J Physiol; 2020 Jul; 598(14):2977-2993. PubMed ID: 30869158
[TBL] [Abstract][Full Text] [Related]
32. Effect of exercise on improving myocardial mitochondrial function in decreasing diabetic cardiomyopathy.
Zhang F; Lin JJ; Tian HN; Wang J
Exp Physiol; 2024 Feb; 109(2):190-201. PubMed ID: 37845840
[TBL] [Abstract][Full Text] [Related]
33. Activation of the
Sun Y; Wang Q; Fang Y; Wu C; Lu G; Chen Z
Dis Model Mech; 2017 Oct; 10(10):1217-1227. PubMed ID: 28801532
[TBL] [Abstract][Full Text] [Related]
34. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy.
Palomer X; Salvadó L; Barroso E; Vázquez-Carrera M
Int J Cardiol; 2013 Oct; 168(4):3160-72. PubMed ID: 23932046
[TBL] [Abstract][Full Text] [Related]
35. Role of AMP-activated protein kinase on cardio-metabolic abnormalities in the development of diabetic cardiomyopathy: A molecular landscape.
Haye A; Ansari MA; Rahman SO; Shamsi Y; Ahmed D; Sharma M
Eur J Pharmacol; 2020 Dec; 888():173376. PubMed ID: 32810493
[TBL] [Abstract][Full Text] [Related]
36. Diazoxide preconditioning of endothelial progenitor cells from streptozotocin-induced type 1 diabetic rats improves their ability to repair diabetic cardiomyopathy.
Ali M; Mehmood A; Anjum MS; Tarrar MN; Khan SN; Riazuddin S
Mol Cell Biochem; 2015 Dec; 410(1-2):267-79. PubMed ID: 26359087
[TBL] [Abstract][Full Text] [Related]
37. Endothelial Dysfunction and Diabetic Cardiomyopathy.
Wang M; Li Y; Li S; Lv J
Front Endocrinol (Lausanne); 2022; 13():851941. PubMed ID: 35464057
[TBL] [Abstract][Full Text] [Related]
38. Myocardial redox status, mitophagy and cardioprotection: a potential way to amend diabetic heart?
Bai T; Wang F; Zheng Y; Liang Q; Wang Y; Kong J; Cai L
Clin Sci (Lond); 2016 Sep; 130(17):1511-21. PubMed ID: 27433024
[TBL] [Abstract][Full Text] [Related]
39. Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy.
Knapp M; Tu X; Wu R
Acta Pharmacol Sin; 2019 Jan; 40(1):1-8. PubMed ID: 29867137
[TBL] [Abstract][Full Text] [Related]
40. EGFR inhibition protects cardiac damage and remodeling through attenuating oxidative stress in STZ-induced diabetic mouse model.
Liang D; Zhong P; Hu J; Lin F; Qian Y; Xu Z; Wang J; Zeng C; Li X; Liang G
J Mol Cell Cardiol; 2015 May; 82():63-74. PubMed ID: 25758431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
